Moderna Inc. has begun studying its Covid-19 vaccine in children aged 6 months to 11 years in the U.S. and Canada, the latest effort to widen the mass-vaccination campaign beyond adults.
The Cambridge, Mass., company said Tuesday that the first children have received doses in the study, which Moderna is conducting in collaboration with the National Institute of Allergy and Infectious Diseases and a division of the Department of Health and Human Services.
“This pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population,” Moderna Chief Executive Stéphane Bancel said.
Author(s): Peter Loftus
Publication Date: 16 March 2021
Publication Site: Wall Street Journal